INDRAPRASTHA MEDICAL CORP Valuation
INDRAMEDCO · Healthcare · Current price ₹350.75
Is INDRAPRASTHA MEDICAL CORP undervalued?
DocStoX estimates the fair value of INDRAPRASTHA MEDICAL CORP at ₹486 per share, versus the current market price of ₹351. That puts the stock about +38.4% below our fair-value estimate, which we read as "Buy". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹137), Relative P/E (₹1,296), Graham floor (₹191), Analyst target (₹550). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹137 (bear) to ₹486 (base) to ₹1,296 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Valuation multiples
INDRAPRASTHA MEDICAL CORP trades at a P/E of 17.5x and a P/B of 4.6x, with a dividend yield of 1.1%. Multiples are most useful compared against the company's own history and its sector peers — see the peer comparison for context.
Understand the ratios
More on INDRAPRASTHA MEDICAL CORP
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.